PDUFA VII: Human Factors Review, Finance Flexibility, REMS, And Manufacturing Get Attention
User fee reauthorization negotiators from US FDA and industry divide into subgroups to tackle specific issues before moving to the broader agreement.
You may also be interested in...
Proposed commitment letter language included a look at eliminating REMS, potentially to more clearly outline the process.
The US FDA, HHS and White House, as well as industry groups, now must sign off on the document.
Richard Pops has publicly complained about the agency’s review performance during COVID, and Alkermes’ application for a mental health product appears to have been held up because of inspection issues.